MENU
Showcases Stock ranks Forex

Cogent Biosciences Inc (COGT)
6.72  0.2 (3.07%) 03-28 16:00
Open: 6.54 Pre. Close: 6.52
High: 6.77 Low: 6.41
Volume: 2,071,837 Market Cap: 698(M)
Stock Technical Analysis
Overall:     
Target: Six months: 8.97
One year: 10.38
Support: Support1: 5.73
Support2: 4.77
Resistance: Resistance1: 7.68
Resistance2: 8.89
Pivot: 6.52
Moving Averages: MA(5): 6.25
MA(20): 6.64
MA(100): 6.40
MA(250): 9.32
MACD: MACD(12,26): -0.10
Signal(12,26,9): -0.05
%K %D: %K(14,3): 38.08
%D(3): 21.88
RSI: RSI(14): 51.46
52-Week: High: 13.5
Low: 3.67
Change(%): -35.6
Average Vol(K): 3-Month: 2258
10-Days: 1912
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 6.78 - 6.807 6.807 - 6.836
Low: 6.345 - 6.373 6.373 - 6.401
Close: 6.673 - 6.723 6.723 - 6.774
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.

[ COGT ] has closed below upper band by 34.7%. Bollinger Bands are 57.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.
Company profile
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Stock chart
Stock News
Thu, 28 Mar 2024
SG Americas Securities LLC Has $1.87 Million Stock Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World

Thu, 28 Mar 2024
SG Americas Securities LLC Raises Stake in Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat

Thu, 28 Mar 2024
Cogent Biosciences (NASDAQ:COGT) Shares Up 10.4% - MarketBeat

Thu, 28 Mar 2024
How To Trade (COGT) - Stock Traders Daily

Mon, 26 Feb 2024
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results - Yahoo Finance

Thu, 22 Feb 2024
Cogent Biosciences stock jumps on Phase 2 data for bezuclastinib (NASDAQ:COGT) - Seeking Alpha

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Neutral
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 103.91
Shares Float (M) 81.95
% Held by Insiders 0.13
% Held by Institutions 92.00
Shares Short (K) 9070
Shares Short Prior Month (K) 5040
Stock Financials
EPS -2.420
Book Value (p.s.) 2.300
Profit Margin
Operating Margin
Return on Assets (ttm) -42.4
Return on Equity (ttm) -74.9
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -1.981
Qtrly Earnings Growth
Operating Cash Flow (M) -153.62
Levered Free Cash Flow (M) -86.68
Stock Valuation
PE Ratio -2.78
PEG Ratio
Price to Book value 2.92
Price to Sales
Price to Cash Flow -4.55
Stock Dividends
Dividend
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android